Autologous hematopoietic cell transplantation: An update for clinicians. Ann Med. 2014:1-14..
Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality. J Clin Oncol. 2013.
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016.
Graft cryopreservation does not impact overall survival allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide for GVHD prophylaxis. Biol Blood Marrow Transplant. 2020.
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the ASBMT. Biol Blood Marrow Transplant. 2015.
Impact of reduced-intensity conditioning regimens on outcomes in diffuse large B-cell lymphoma undergoing allogeneic transplantation. Biol Blood Marrow Transplant. 2020..
Plerixafor and Abbreviated-course G-CSF for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. Biol Blood Marrow Transplant. 2014.
Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem-cell Transplant. Biol Blood Marrow Transplant. 2019.
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018.
Ruxolitinib: A potential treatment for corticosteroid refractory acute graft-versus-host disease. Expert Opin Investig Drugs. 2020..
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4(1):47-54.